Study Suggests Wegovy Effectiveness in Children as Young as Six

Novo Nordisk has released data from a phase 3 clinical trial indicating that the weight-loss medication Wegovy may be effective in treating obesity in children aged 6 to 11. The findings, presented at an obesity medicine conference, showed that participants taking semaglutide—the active ingredient in the drug—experienced a reduction in body mass index (BMI) of 10% or more.
After 68 weeks, nearly 40% of children in the semaglutide group no longer met the clinical definition of obesity, compared to nearly all patients in the placebo group who retained a status of obesity. Currently, the Food and Drug Administration (FDA) has approved Wegovy for use in children as young as 12, though Novo Nordisk intends to petition the agency to lower the age threshold.
The medical community remains divided on the broad application of glucagon-like peptide-1 (GLP-1) receptor agonists, such as Wegovy, for younger children. The World Health Organization (WHO) currently advises against pharmacological weight-loss treatments for those under age 10, prioritizing lifestyle interventions such as diet and exercise. The Centers for Disease Control and Prevention reports that approximately one in five U.S. children and adolescents have obesity.
Dr. Mary Pat Gallagher, director of the division of pediatric endocrinology and diabetes at Hassenfeld Children’s Hospital at NYU Langone, characterized the trial findings as “a remarkable result.” She noted that treating obesity early could prevent severe health consequences, such as fatty liver disease and obstructive sleep apnea, potentially reducing the need for multiple medications. “Instead of taking a blood pressure medication and some drug to treat fat in your liver or wearing a CPAP or a BiPAP at night for your obstructive sleep apnea, by treating obesity, you could be treating all of those with just one medication,” Gallagher said.
Conversely, some experts emphasized the necessity of monitoring side effects and potential long-term impacts. The trial reported higher rates of gastrointestinal issues among the semaglutide group: 70% of participants experienced vomiting, 62% dealt with diarrhea, and 58% had nausea, compared to significantly lower rates in the placebo group. Dr. Jade Cobern, a physician board certified in pediatrics and preventive medicine, noted that the impact of these side effects on a young child’s daily life—such as their ability to attend and learn in school—requires close oversight.
The study also identified a difference in linear growth, with children in the semaglutide group growing approximately 1.3 inches less than those in the placebo group. Cobern argued that further follow-up is essential to fully understand the drug’s long-term effects on child growth and body composition.
Despite the risks, Gallagher maintained that the potential benefits for children with obesity-related conditions justify the treatment. Cobern agreed that the medication could serve as a valuable tool when lifestyle interventions are insufficient, though she cautioned against viewing it as a standalone or first-line approach.